Company
ability.bio
Precision depletion of pathogenic T cells for autoimmune and inflammatory diseases
Also known as Ability Biotherapeutics
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
Claim, correct or request removal
Record updated 28 September 2026
About
Our proprietary AbiLeap discovery engine combines massively parallel, continuously learning artificial intelligence with an extensive proprietary database of therapeutic antibody sequences and antigen-antibody interactions to generate fully-human antibodies with exquisite selectivity and developability.
Funding snapshot
- Total raised
- $18MSum of rounds, as of 2026-09-17Source (opens in a new tab)
- Latest round
- Seed extension, $18M2024-06-18
Funding rounds
- Seed extension
- $18M2024-06-18, Company stated
Products
- Other
- Leap 1121
Loading relationship preview